The findings of this study open several promising avenues for upcoming research to advance the clinical utility of FCRL1 and BAFF in non-Hodgkin lymphoma (NHL), translating molecular insights into actionable strategies for improving diagnostic accuracy, prognostic precision, and therapeutic outcomes in DLBCL patients, especially. The gene discussed is FCRL1; the disease is diffuse large B-cell lymphoma.